Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Psoriasis is a chronic systemic inflammatory disease that primarily affects the skin and is
associated with multiple comorbidities with a considerable reduction in quality of life of …

Background Risankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits
IL-23, is currently approved for the treatment of moderate-to-severe plaque psoriasis and …

Abstract Background Network meta‐analyses (NMAs) have become successful in
addressing gaps in the comparative effectiveness of systemic treatments in moderate‐to …

Introduction: Several new treatments have been developed for psoriatic disease, an
inflammatory condition that involves skin and joints. Notwithstanding, few studies have made …

Background Psoriasis, an immune-mediated chronic inflammatory disease primarily
affecting skin and joints, has varying prevalence rates globally. It manifests in five types, with …

Introduction Novel therapies have allowed psoriasis patients to achieve high levels of skin
clearance and meaningful improvements in health-related quality of life measures; however …

Psoriasis is a chronic and debilitating inflammatory immune-mediated skin disorder. Several
cytokines including interleukin (IL)-23 were demonstrated to play a central role in the …

In this study, our purpose was to systematically evaluate the efficacy and safety of interleukin‐
23 (IL‐23)‐targeted drugs in the treatment of moderate‐to‐severe psoriasis and provide an …

Network meta‐analyses (NMAs) increasingly assist in treatment decisions in disease areas
such as psoriasis, where data from multiple clinical trials (CTs) on a growing number of …